image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - IE
$ 7.75
-3.12 %
$ 747 M
Market Cap
-10.33
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one AVDL stock under the worst case scenario is HIDDEN Compared to the current market price of 7.75 USD, Avadel Pharmaceuticals plc is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one AVDL stock under the base case scenario is HIDDEN Compared to the current market price of 7.75 USD, Avadel Pharmaceuticals plc is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one AVDL stock under the best case scenario is HIDDEN Compared to the current market price of 7.75 USD, Avadel Pharmaceuticals plc is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
28 M REVENUE
0.00%
-138 M OPERATING INCOME
-39.86%
-160 M NET INCOME
-16.59%
-129 M OPERATING CASH FLOW
-82.79%
-50.1 M INVESTING CASH FLOW
-62.85%
135 M FINANCING CASH FLOW
830.59%
50 M REVENUE
20.53%
-327 K OPERATING INCOME
97.43%
-2.62 M NET INCOME
81.01%
-6.89 M OPERATING CASH FLOW
62.11%
5.06 M INVESTING CASH FLOW
-51.47%
1.18 M FINANCING CASH FLOW
62.79%
Balance Sheet Avadel Pharmaceuticals plc
image
Current Assets 134 M
Cash & Short-Term Investments 105 M
Receivables 13.4 M
Other Current Assets 15.7 M
Non-Current Assets 30.5 M
Long-Term Investments 0
PP&E 13.1 M
Other Non-Current Assets 17.4 M
Current Liabilities 36.9 M
Accounts Payable 11.4 M
Short-Term Debt 1.87 M
Other Current Liabilities 23.6 M
Non-Current Liabilities 40.1 M
Long-Term Debt 34.4 M
Other Non-Current Liabilities 5.65 M
EFFICIENCY
Earnings Waterfall Avadel Pharmaceuticals plc
image
Revenue 28 M
Cost Of Revenue 846 K
Gross Profit 27.1 M
Operating Expenses 165 M
Operating Income -138 M
Other Expenses 22.4 M
Net Income -160 M
RATIOS
96.97% GROSS MARGIN
96.97%
-492.97% OPERATING MARGIN
-492.97%
-573.17% NET MARGIN
-573.17%
-182.67% ROE
-182.67%
-97.32% ROA
-97.32%
-113.16% ROIC
-113.16%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Avadel Pharmaceuticals plc
image
Net Income -160 M
Depreciation & Amortization 1.77 M
Capital Expenditures 0
Stock-Based Compensation 15.8 M
Change in Working Capital -3 M
Others 32.4 M
Free Cash Flow -129 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Avadel Pharmaceuticals plc
image
Wall Street analysts predict an average 1-year price target for AVDL of $20.9 , with forecasts ranging from a low of $9 to a high of $30 .
AVDL Lowest Price Target Wall Street Target
9 USD 16.13%
AVDL Average Price Target Wall Street Target
20.9 USD 169.12%
AVDL Highest Price Target Wall Street Target
30 USD 287.10%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Avadel Pharmaceuticals plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
406 K USD 4
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
29 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
1 month ago
Dec 13, 2024
Bought 24 K USD
MCHUGH THOMAS S
Chief Financial Officer
+ 2300
10.4429 USD
1 month ago
Dec 11, 2024
Bought 52.4 K USD
MCHUGH THOMAS S
Chief Financial Officer
+ 5000
10.4865 USD
1 month ago
Dec 09, 2024
Bought 3.95 K USD
Divis Gregory J
Chief Executive Officer
+ 402
9.82 USD
1 month ago
Dec 06, 2024
Bought 95.8 K USD
Divis Gregory J
Chief Executive Officer
+ 9598
9.977 USD
1 month ago
Dec 10, 2024
Bought 100 K USD
Glass Geoffrey Michael
Director
+ 10204
9.8 USD
1 month ago
Dec 10, 2024
Bought 99.6 K USD
Glass Geoffrey Michael
Director
+ 10075
9.89 USD
1 month ago
Dec 06, 2024
Bought 30.6 K USD
Palczuk Linda
Director
+ 3000
10.1892 USD
1 year ago
Jan 16, 2024
Bought 29 K USD
MCHUGH THOMAS S
Chief Financial Officer
+ 2000
14.5 USD
1 year ago
Dec 28, 2023
Sell 1.09 M USD
McCamish Mark Anthony
Director
- 75000
14.53 USD
1 year ago
Aug 11, 2023
Sell 433 K USD
McCamish Mark Anthony
Director
- 28975
14.9306 USD
1 year ago
Aug 14, 2023
Bought 28.9 K USD
MCHUGH THOMAS S
Chief Financial Officer
+ 2000
14.45 USD
1 year ago
Aug 10, 2023
Bought 188 K USD
Glass Geoffrey Michael
Director
+ 14000
13.4 USD
1 year ago
Aug 10, 2023
Bought 132 K USD
Divis Gregory J
Chief Executive Officer
+ 10000
13.1997 USD
1 year ago
May 18, 2023
Bought 181 K USD
Ende Eric J
Director
+ 13000
13.9308 USD
1 year ago
May 09, 2023
Bought 36.9 K USD
Palczuk Linda
Director
+ 2500
14.76 USD
2 years ago
Dec 23, 2022
Bought 14.4 K USD
Palczuk Linda
Director
+ 2000
7.2025 USD
2 years ago
Nov 29, 2022
Bought 39 K USD
MCHUGH THOMAS S
Chief Financial Officer
+ 5000
7.8 USD
2 years ago
Nov 22, 2022
Bought 156 K USD
Ende Eric J
Director
+ 20000
7.8025 USD
2 years ago
May 31, 2022
Bought 96.3 K USD
Glass Geoffrey Michael
Director
+ 45000
2.14 USD
2 years ago
Jun 01, 2022
Bought 96.3 K USD
Glass Geoffrey Michael
director:
+ 45000
2.14 USD
2 years ago
May 31, 2022
Bought 45.5 K USD
Ende Eric J
director:
+ 20000
2.2748 USD
2 years ago
May 31, 2022
Bought 32.4 K USD
Ende Eric J
Director
+ 15000
2.1596 USD
2 years ago
May 27, 2022
Bought 16 K USD
Palczuk Linda
director:
+ 10000
1.6 USD
2 years ago
May 27, 2022
Bought 107 K USD
MCHUGH THOMAS S
Chief Financial Officer
+ 50000
2.1379 USD
2 years ago
May 27, 2022
Bought 36.7 K USD
Ende Eric J
director:
+ 15000
2.4498 USD
2 years ago
May 27, 2022
Bought 102 K USD
Divis Gregory J
Chief Executive Officer
+ 50000
2.05 USD
2 years ago
May 27, 2022
Bought 84.5 K USD
Thornton Peter J.
director:
+ 50000
1.69 USD
4 years ago
Sep 18, 2020
Bought 24 K USD
MCHUGH THOMAS S
Chief Financial Officer
+ 4000
6 USD
4 years ago
Sep 17, 2020
Bought 305 K USD
McCamish Mark Anthony
Director
+ 52398
5.8256 USD
4 years ago
Sep 16, 2020
Bought 680 K USD
McCamish Mark Anthony
Director
+ 118602
5.7332 USD
4 years ago
Sep 17, 2020
Bought 98.4 K USD
Ende Eric J
Director
+ 17000
5.7868 USD
4 years ago
Aug 28, 2020
Bought 50.8 K USD
MCHUGH THOMAS S
Chief Financial Officer
+ 7500
6.7702 USD
4 years ago
Aug 28, 2020
Bought 32.6 K USD
Glass Geoffrey Michael
Director
+ 4800
6.7833 USD
4 years ago
Aug 13, 2020
Bought 77.8 K USD
MCHUGH THOMAS S
Chief Financial Officer
+ 10000
7.7814 USD
4 years ago
Aug 14, 2020
Bought 19.8 K USD
Palczuk Linda
Director
+ 2500
7.9399 USD
4 years ago
Aug 13, 2020
Bought 29.6 K USD
Ende Eric J
Director
+ 3800
7.8 USD
4 years ago
Aug 13, 2020
Bought 9.29 K USD
Ende Eric J
Director
+ 1200
7.74 USD
4 years ago
Aug 13, 2020
Bought 50.4 K USD
Glass Geoffrey Michael
Director
+ 6500
7.76 USD
4 years ago
Aug 12, 2020
Bought 50 K USD
Glass Geoffrey Michael
Director
+ 6500
7.7 USD
4 years ago
Aug 12, 2020
Bought 116 K USD
Ende Eric J
Director
+ 15000
7.757 USD
4 years ago
Aug 12, 2020
Bought 101 K USD
Divis Gregory J
Chief Executive Officer
+ 13000
7.7812 USD
5 years ago
Dec 12, 2019
Sell 22.2 K USD
Hatten Sandra L
See Remarks
- 3072
7.23 USD
5 years ago
Dec 04, 2019
Bought 59.7 K USD
Ende Eric J
Director
+ 10000
5.97 USD
5 years ago
Dec 03, 2019
Bought 44.3 K USD
Palczuk Linda
Director
+ 7500
5.91 USD
5 years ago
Nov 18, 2019
Bought 74.8 K USD
Glass Geoffrey Michael
Director
+ 15000
4.99 USD
5 years ago
Nov 15, 2019
Bought 25 K USD
Glass Geoffrey Michael
Director
+ 5000
4.99 USD
5 years ago
Nov 15, 2019
Bought 97.5 K USD
DIVIS GREG J
Chief Executive Officer
+ 19000
5.13 USD
5 years ago
Nov 15, 2019
Bought 49.8 K USD
Ende Eric J
Director
+ 10000
4.9762 USD
6 years ago
Dec 14, 2018
Sell 21 K USD
KANAN MICHAEL F
See Remarks
- 8429
2.494 USD
6 years ago
Dec 14, 2018
Sell 1.66 K USD
GUSKY DAVID P
Controller & CAO
- 617
2.6834 USD
6 years ago
Dec 14, 2018
Sell 8.18 K USD
Hatten Sandra L
See Remarks
- 3173
2.579 USD
6 years ago
Aug 10, 2018
Sell 80 K USD
ANDERSON MICHAEL S
Chief Executive Officer
- 16297
4.906 USD
6 years ago
Aug 10, 2018
Sell 30.9 K USD
Hatten Sandra L
See Remarks
- 6290
4.906 USD
6 years ago
Jun 26, 2018
Bought 11.2 K USD
KANAN MICHAEL F
See Remarks
+ 1967
5.7 USD
6 years ago
Jun 26, 2018
Bought 15.1 K USD
ANDERSON MICHAEL S
Chief Executive Officer
+ 2500
6.04 USD
6 years ago
Jun 26, 2018
Bought 96 K USD
DIVIS GREG J
See Remarks
+ 16000
6 USD
6 years ago
Jun 26, 2018
Bought 57.7 K USD
THOMPSON PHILLANDAS T.
See Remarks
+ 10000
5.77 USD
6 years ago
Jun 25, 2018
Sell 683 K USD
Flynn James E
10 percent owner
- 114034
5.9922 USD
6 years ago
May 24, 2018
Bought 19.3 K USD
ANDERSON MICHAEL S
Chief Executive Officer
+ 3000
6.44 USD
7 years ago
Dec 15, 2017
Bought 607 K USD
STAPLETON CRAIG R
Director
+ 70000
8.671 USD
7 years ago
Dec 15, 2017
Bought 607 K USD
STAPLETON CRAIG R
Director
+ 70000
8.671 USD
7 years ago
Dec 07, 2017
Bought 44.3 K USD
ANDERSON MICHAEL S
Chief Executive Officer
+ 5000
8.859 USD
7 years ago
Nov 27, 2017
Sell 2.38 M USD
STAPLETON CRAIG R
Director
- 254265
9.351 USD
7 years ago
Sep 21, 2017
Bought 50.2 K USD
Thornton Peter J.
Director
+ 5155
9.741 USD
7 years ago
Sep 14, 2017
Bought 19.7 K USD
Hatten Sandra L
See Remarks
+ 2100
9.359 USD
7 years ago
Sep 13, 2017
Bought 4.67 K USD
Hatten Sandra L
See Remarks
+ 500
9.346 USD
7 years ago
Sep 12, 2017
Bought 20.2 K USD
Hatten Sandra L
See Remarks
+ 2200
9.19 USD
7 years ago
Sep 12, 2017
Bought 11 K USD
Hatten Sandra L
See Remarks
+ 1200
9.15 USD
7 years ago
Sep 13, 2017
Bought 46.8 K USD
THOMPSON PHILLANDAS T.
See Remarks
+ 5000
9.36 USD
7 years ago
Sep 12, 2017
Bought 190 K USD
STAPLETON CRAIG R
Director
+ 20000
9.518 USD
7 years ago
Sep 12, 2017
Bought 98.8 K USD
DIVIS GREG J
See Remarks
+ 10600
9.317 USD
7 years ago
Sep 12, 2017
Bought 39.2 K USD
ANDERSON MICHAEL S
Chief Executive Officer
+ 4000
9.795 USD
7 years ago
Jun 22, 2017
Sell 1.08 M USD
Broadfin Healthcare Master Fund Ltd
10 percent owner
- 100000
10.8 USD
7 years ago
Jun 23, 2017
Sell 1.71 M USD
Broadfin Healthcare Master Fund Ltd
10 percent owner
- 161000
10.6 USD
7 years ago
Jun 15, 2017
Sell 278 K USD
CERUTTI GUILLAUME
Director
- 26560
10.46 USD
7 years ago
May 19, 2017
Bought 25 K USD
ANDERSON MICHAEL S
Chief Executive Officer
+ 2500
10 USD
7 years ago
May 22, 2017
Bought 165 K USD
STAPLETON CRAIG R
Director
+ 16900
9.76 USD
7 years ago
May 19, 2017
Bought 30.5 K USD
STAPLETON CRAIG R
Director
+ 3100
9.83 USD
7 years ago
May 18, 2017
Bought 110 K USD
STAPLETON CRAIG R
Director
+ 11013
9.98 USD
8 years ago
Nov 29, 2016
Bought 108 K USD
STAPLETON CRAIG R
Director
+ 10000
10.85 USD
8 years ago
Nov 28, 2016
Bought 107 K USD
STAPLETON CRAIG R
Director
+ 10000
10.737 USD
8 years ago
Nov 21, 2016
Bought 21.3 K USD
ANDERSON MICHAEL S
Chief Executive Officer
+ 2000
10.637 USD
8 years ago
Sep 22, 2016
Sell 202 K USD
FILDES FRANCIS
Director
- 15000
13.45 USD
8 years ago
Sep 02, 2016
Bought 28.2 K USD
ANDERSON MICHAEL S
Chief Executive Officer
+ 2000
14.12 USD
8 years ago
Sep 01, 2016
Bought 135 K USD
STAPLETON CRAIG R
Director
+ 10000
13.519 USD
8 years ago
Aug 26, 2016
Bought 125 K USD
STAPLETON CRAIG R
Director
+ 9122
13.67 USD
8 years ago
Aug 26, 2016
Bought 150 K USD
STAPLETON CRAIG R
Director
+ 10878
13.83 USD
8 years ago
Aug 22, 2016
Bought 71.5 K USD
ANDERSON MICHAEL S
Chief Executive Officer
+ 5000
14.2957 USD
8 years ago
May 16, 2016
Bought 22.3 K USD
STAPLETON CRAIG R
Director
+ 2415
9.25 USD
8 years ago
May 13, 2016
Bought 229 K USD
STAPLETON CRAIG R
Director
+ 24813
9.211 USD
8 years ago
May 12, 2016
Bought 44.2 K USD
ANDERSON MICHAEL S
Chief Executive Officer
+ 5000
8.84 USD
8 years ago
Mar 22, 2016
Bought 111 K USD
THOMPSON PHILLANDAS T.
See Remarks
+ 10000
11.103 USD
8 years ago
Mar 18, 2016
Bought 55.2 K USD
ANDERSON MICHAEL S
Chief Executive Officer
+ 5000
11.044 USD
8 years ago
Mar 18, 2016
Bought 33 K USD
Hatten Sandra L
Sr. VP, Quality & Reg Affairs
+ 3000
11.01 USD
8 years ago
Mar 14, 2016
Bought 1.04 M USD
STAPLETON CRAIG R
Director
+ 100000
10.394 USD
8 years ago
Mar 14, 2016
Bought 97.4 K USD
ANDERSON MICHAEL S
Chief Executive Office
+ 10000
9.735 USD
7. News
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to twelve (12) new employees to purchase an aggregate of 131,700 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel's 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants. globenewswire.com - 1 week ago
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8 DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, January 8, 2025, to provide a corporate update and discuss the Company's preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com - 2 weeks ago
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20 at 7:30 a.m. GMT / 2:30 a.m. ET. globenewswire.com - 2 months ago
Avadel Pharmaceuticals plc (AVDL) Q3 2024 Earnings Call Transcript Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Austin Murtagh - Director, Precision AQ Greg Divis - CEO Richard Kim - CCO Jennifer Gudeman - SVP, Medical & Clinical Affairs Tom McHugh - CFO Conference Call Participants Andrew Tsai - Jefferies François Brisebois - Oppenheimer Oren Livnat - H.C. Wainwright Ami Fadia - Needham David Amsellem - Piper Sandler Operator Good day everyone and welcome to today's Avadel Pharmaceuticals 3Q 2024 Earnings Call. seekingalpha.com - 2 months ago
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation DUBLIN, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that yesterday, the U.S. District Court for the District of Columbia (“Court”) ruled in favor of the Food and Drug Administration (“FDA”) in a suit brought by Jazz Pharmaceuticals Inc. (“Jazz”) under the Administrative Procedure Act regarding the FDA's approval of LUMRYZTM, the first and only once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in adults with narcolepsy. With this ruling, the approval of LUMRYZ is upheld based on the FDA's determination that LUMRYZ is clinically superior to Jazz's twice-nightly oxybate products. globenewswire.com - 2 months ago
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy. zacks.com - 3 months ago
US FDA expands approval for Avadel's sleep disorder drug The U.S. Food and Drug Administration has approved Avadel Pharmaceuticals' sleep disorder drug for children aged 7 years and older, broadening its use and heating up competition for widely used treatments from Jazz Pharma. reuters.com - 3 months ago
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy -- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— globenewswire.com - 3 months ago
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences DUBLIN, Ireland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: globenewswire.com - 4 months ago
Avadel Pharmaceuticals plc (AVDL) Q2 2024 Earnings Call Transcript Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Austin Murtagh - Director, Precision AQ Greg Divis - Chief Executive Officer Richard Kim - Chief Commercial Officer Jennifer Gudeman - Senior Vice President, Medical & Clinical Affairs Tom McHugh - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies François Brisebois - Oppenheimer Ami Fadia - Needham & Company David Amsellem - Piper Sandler Marc Goodman - Leerink Fatima Amanat - UBS Oren Livnat - H.C. Wainwright Myriam Belghiti - LifeSci Capital Matt Kaplan - Ladenburg Thalmann Brandon Folkes - Rodman & Renshaw Operator Greetings, and welcome to Avadel Pharmaceuticals' Second Quarter 2024 Earnings Call. seekingalpha.com - 5 months ago
Does Avadel (AVDL) Have the Potential to Rally 43.6% as Wall Street Analysts Expect? The mean of analysts' price targets for Avadel (AVDL) points to a 43.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 5 months ago
8. Profile Summary

Avadel Pharmaceuticals plc AVDL

image
COUNTRY IE
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 747 M
Dividend Yield 0.00%
Description Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Contact 10 Earlsfort Terrace, Dublin, 2 https://www.avadel.com
IPO Date June 7, 1996
Employees 154
Officers Mr. Jerad G. Seurer General Counsel & Company Secretary Mr. Gregory J. Davis Vice President of Corporate and Business Development Mr. Thomas S. McHugh Senior Vice President, Principal Financial and Accounting Officer & Chief Financial Officer Dr. Jordan S. Dubow M.D. Consultant Mr. Gregory J. Divis Jr. Chief Executive Officer & Director Mr. Mark W. Elrod Vice President of Sales Ms. Angie Woods Vice President of People & Culture Dr. Jason M. Vaughn Senior Vice President of Technical Operations Ms. Jennifer Gudeman PharmD Senior Vice President of Medical & Clinical Affairs